Trequinsin hydrochlorideExtremely potent inhibitor of PDE3 CAS# 78416-81-6 |
- Thrombin Receptor Agonist Peptide
Catalog No.:BCC3950
CAS No.:137339-65-2
- SLIGRL-NH2
Catalog No.:BCC3947
CAS No.:171436-38-7
- TFLLR-NH2
Catalog No.:BCC3948
CAS No.:197794-83-5
- AY-NH2
Catalog No.:BCC3949
CAS No.:352017-71-1
- ML161
Catalog No.:BCC3642
CAS No.:423735-93-7
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 78416-81-6 | SDF | Download SDF |
| PubChem ID | 3060974 | Appearance | Powder |
| Formula | C24H28ClN3O3 | M.Wt | 441.95 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Synonyms | HL-725 | ||
| Solubility | Soluble to 100 mM in DMSO and to 100 mM in ethanol | ||
| Chemical Name | 9,10-dimethoxy-3-methyl-2-(2,4,6-trimethylphenyl)imino-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one;hydrochloride | ||
| SMILES | CC1=CC(=C(C(=C1)C)N=C2C=C3C4=CC(=C(C=C4CCN3C(=O)N2C)OC)OC)C.Cl | ||
| Standard InChIKey | DTCZZBVPTHVXFA-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C24H27N3O3.ClH/c1-14-9-15(2)23(16(3)10-14)25-22-13-19-18-12-21(30-6)20(29-5)11-17(18)7-8-27(19)24(28)26(22)4;/h9-13H,7-8H2,1-6H3;1H | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Extremely potent inhibitor of cGMP-inhibited phosphodiesterase (PDE3; IC50 = 250 pM). Potently inhibits arachidonic acid-induced aggregation of human platelets (IC50 = 50 pM). Orally active antihypertensive agent; reduces systemic blood pressure in both normotensive and hypertensive animal models. |
Trequinsin hydrochloride Dilution Calculator
Trequinsin hydrochloride Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.2627 mL | 11.3135 mL | 22.627 mL | 45.254 mL | 56.5675 mL |
| 5 mM | 0.4525 mL | 2.2627 mL | 4.5254 mL | 9.0508 mL | 11.3135 mL |
| 10 mM | 0.2263 mL | 1.1313 mL | 2.2627 mL | 4.5254 mL | 5.6567 mL |
| 50 mM | 0.0453 mL | 0.2263 mL | 0.4525 mL | 0.9051 mL | 1.1313 mL |
| 100 mM | 0.0226 mL | 0.1131 mL | 0.2263 mL | 0.4525 mL | 0.5657 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Milrinone
Catalog No.:BCC4374
CAS No.:78415-72-2
- 1,7-Dihydroxy-2,3-dimethoxyxanthone
Catalog No.:BCN7523
CAS No.:78405-33-1
- MY-5445
Catalog No.:BCC6645
CAS No.:78351-75-4
- Pyranojacareubin
Catalog No.:BCN7429
CAS No.:78343-62-1
- Nocamycin I
Catalog No.:BCN1845
CAS No.:78339-49-8
- PCI-24781 (CRA-024781)
Catalog No.:BCC2155
CAS No.:783355-60-2
- MLN120B
Catalog No.:BCC1772
CAS No.:783348-36-7
- MRK 016
Catalog No.:BCC6070
CAS No.:783331-24-8
- H-D-1-Nal-OH
Catalog No.:BCC3281
CAS No.:78306-92-0
- 7-Ethylcamptothecin
Catalog No.:BCN2480
CAS No.:78287-27-1
- Ecliptasaponin A
Catalog No.:BCN3843
CAS No.:78285-90-2
- Nepafenac
Catalog No.:BCC1258
CAS No.:78281-72-8
- 5,7,3'-Trihydroxy-6,4',5'-trimethoxyflavone
Catalog No.:BCN1353
CAS No.:78417-26-2
- RGB-286638
Catalog No.:BCC5519
CAS No.:784210-87-3
- RGB-286638 free base
Catalog No.:BCC5520
CAS No.:784210-88-4
- Deacetyltaxol
Catalog No.:BCN2820
CAS No.:78432-77-6
- 19-Hydroxybaccatin III
Catalog No.:BCN4330
CAS No.:78432-78-7
- 7-Epi 10-Desacetyl Paclitaxel
Catalog No.:BCC1314
CAS No.:78454-17-8
- Enterolakton
Catalog No.:BCC8170
CAS No.:78473-71-9
- Praeruptorin E
Catalog No.:BCN2591
CAS No.:78478-28-1
- 7-Epi-10-deacetylcephalomannine
Catalog No.:BCN7673
CAS No.:78479-12-6
- N-trans-Feruloyl-3-methoxytyramine
Catalog No.:BCN4331
CAS No.:78510-19-7
- PSB 069
Catalog No.:BCC7416
CAS No.:78510-31-3
- Asperumine
Catalog No.:BCN2039
CAS No.:78513-20-9
Role of plasma adenosine in the antiplatelet action of HL 725, a potent inhibitor of cAMP phosphodiesterase: species differences.[Pubmed:2821650]
Thromb Res. 1987 Jul 15;47(2):191-200.
The potent inhibitor of platelet cAMP phosphodiesterase (PDE) HL 725 (9,10-Dimethoxy-2-mesitylimino-3-methyl-3, 4,6,7-tetrahydro-2H-pyrimido(6,1-A)-isoquinoline-4-one-hydrochloride), was examined for its effects on human and rat platelet aggregation. Strong inhibitory effects are seen on collagen-induced platelet aggregation both in rat platelet-rich plasma (PRP) (IC50, 54 +/- 12 nM) and whole blood (IC50, 57 +/- 25 nM). Compared to the effects on rat platelets, HL 725 is about two-fold less inhibitory in human PRP (IC50, 94 +/- 29 nM) and whole blood (IC50, 126 +/- 50 nM). The inhibitory action of HL 725 can be reversed by washing and resuspension of the platelets, suggesting that HL 725 does not bind tightly to cAMP PDE. If human or rat PRP is pretreated with adenosine deaminase, an enzyme that degrades adenosine or 2',5'-dideoxyadenosine, an inhibitor of adenylate cyclase, the inhibitory effect of HL 725 is reversed. Similar blockade of the inhibitory actions of several other inhibitors of cAMP PDE such as RA 233, RX-RA 69 (analogs of dipyridamole) and oxagrelate is seen by adenosine deaminase pretreatment. The nucleoside transport inhibitors, dilazep and dipyridamole which are non-inhibitory alone to platelet aggregation, strongly potentiate (about 10-fold) the inhibitory action of HL 725 on collagen-induced platelet aggregation in human whole blood. However, if the whole blood is pretreated with adenosine deaminase, no inhibitory effect of dipyridamole plus HL 725 is seen on platelet aggregation. These studies demonstrate that plasma adenosine plays a crucial role in the antiaggregatory actions of HL 725 and several other inhibitors of cAMP PDE both in human and rat blood.
Trequinsin, a potent new antihypertensive vasodilator in the series of 2-(arylimino)-3-alkyl-9,10-dimethoxy-3,4,6,7-tetrahydro-2H-py rim ido [6,1-a]isoquinolin-4-ones.[Pubmed:6492077]
J Med Chem. 1984 Nov;27(11):1470-80.
Series of 3-substituted-9,10-dimethoxy-3,4,6,7-tetrahydro-2H-pyrimido [6,1-a]isoquinoline-2,4-diones and 2-substituted-9,10-dimethoxy-6,7-dihydro-4H-pyrimido [6,1-a]isoquinolin-4-ones were synthesized and tested for blood pressure lowering properties in anesthetized normotensive cats and conscious spontaneously hypertensive rats. Several compounds in the 2-(arylamino)-9,10-dimethoxy-6,7-dihydro-4H-pyrimido [6,1-a]isoquinolin-4-one series display a high order of activity. The most active compounds are the alkyl derivatives of the 2-mesitylamino/2-mesitylimino tautomeric forms. The 2-(mesitylimino)-3-methyl analogue trequinsin is a potent antihypertensive agent and displays a hemodynamic profile characteristic of an arteriolar dilator. It is also a potent inhibitor of both cAMP phosphodiesterase and platelet aggregation.
HL 725, an extremely potent inhibitor of platelet phosphodiesterase and induced platelet aggregation in vitro.[Pubmed:6294426]
Life Sci. 1982 Nov 8;31(19):2037-43.
The new pyrimido-isoquinoline compound HL 725 is an extremely potent inhibitor of the aggregation of human platelets induced in vitro by ADP, collagen, thrombin and epinephrine. The aggregation induced by 0,5 mM arachidonic acid is inhibited about 50% with 50 pM HL 725. Thus the potency of HL 725 is higher than that of prostacyclin, the most active natural inhibitor of aggregation. We hypothesize that HL 725 inhibits the enzymatic degradation of cyclic adenosine 3', 5'-monophosphate (cAMP) in the platelets. In accordance with this proposal is the strong inhibitory action on cAMP phosphodiesterase extracted from human platelets. About 250 pM HL 725 inhibited 50% of the activity of this enzyme at a substrate concentration of 0.5 microM. A marked elevation of cAMP levels in human platelets could be demonstrated after incubation in vitro with 100 nM HL 725.
